NeoTX Announces FDA Clearance of IND for Phase 2 Clinical Trial of Naptumomab Estafenatox (NAP), its lead Tumor Targeted Superantigen Candidate

by NASDAQ Market News April 19, 2021

NASDAQ Market News
Click here to email author

FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer

Number of Shares and Voting Rights of Innate Pharma as of April 1, 2021

Ads